Selected NCI-Supported Trials
Descriptions of some of the major clinical trials that NCI supports to test promising cancer treatments and screening methods.
NCI-COG Pediatric MATCHUpdated: October 2, 2018
In this precision medicine clinical trial, children and adolescents with advanced cancers whose tumors have particular genetic mutations are being treated with drugs designed to target those mutations.
NCI-MATCH Trial (Molecular Analysis for Therapy Choice)Updated: August 21, 2018
Information about the NCI-MATCH precision medicine trial, in which researchers will examine tumor tissue from patients with advanced solid tumors and lymphomas that have stopped responding to treatment and assign patients to treatment arms based on the molecular profiles of their disease.
The ALCHEMIST Lung Cancer TrialsUpdated: July 24, 2017
A collection of material about the ALCHEMIST lung cancer trials that will examine tumor tissue from patients with certain types of early-stage, completely resected non-small cell lung cancer for gene mutations in the EGFR and ALK genes, and assign patients with these gene mutations to treatment trials testing post-surgical use of drugs targeted against these mutations.
Lung-MAP: Master Protocol for Lung CancerUpdated: January 31, 2019
The Lung Cancer Master Protocol, or Lung-MAP, is a precision medicine research study for people with advanced non-small cell lung cancer that has continued to grow after treatment. Patients are assigned to different study drug combinations based on the results of genomic profiling of their tumors.
The ALTTO Breast Cancer TrialUpdated: June 1, 2014
A collection of material about the Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation, or ALTTO, study that will compare the targeted agents lapatinib and trastuzumab alone, in sequence, or in combination as adjuvant therapy for HER2-positive breast cancer.
The TAILORx Breast Cancer TrialUpdated: June 4, 2018
A collection of material about the Trial Assigning IndividuaLized Options for Treatment (Rx), or TAILORx, which will examine whether a molecular test can assign women with early-stage breast cancer to the most appropriate and effective treatment.
Testing and Screening Trials
TMIST (Tomosynthesis Mammographic Imaging Screening Trial)
TMIST is a randomized breast screening trial that compares two Food and Drug Administration (FDA)-approved types of digital mammography, standard digital mammography (2-D) with a newer technology called tomosynthesis mammography (3-D).
National Lung Screening Trial
Information about the National Lung Screening Trial (NLST), a research study sponsored by the National Cancer Institute that used low-dose helical CT scans or chest X-ray to screen men and women at risk for lung cancer.
Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial
A large-scale clinical trial to determine whether certain cancer screening tests reduce deaths from prostate, lung, colorectal, and ovarian cancer. In addition, there are numerous epidemiologic and ancillary studies going on that will answer other crucial questions about these cancers and these screening tests.